NYSE:CRY

Stock Analysis Report

Executive Summary

CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide.

Snowflake

Fundamentals

Reasonable growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has CryoLife's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.8%

CRY

-1.6%

US Medical Equipment

0.07%

US Market


1 Year Return

-28.2%

CRY

13.8%

US Medical Equipment

8.9%

US Market

Return vs Industry: CRY underperformed the US Medical Equipment industry which returned 13.8% over the past year.

Return vs Market: CRY underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

CRYIndustryMarket
7 Day2.8%-1.6%0.07%
30 Day-19.1%-4.3%-0.3%
90 Day-22.9%-4.3%-1.6%
1 Year-28.2%-28.2%14.7%13.8%11.3%8.9%
3 Year39.6%39.6%70.7%65.6%46.3%36.8%
5 Year131.3%128.1%117.3%93.5%62.1%44.3%

Price Volatility Vs. Market

How volatile is CryoLife's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CryoLife undervalued compared to its fair value and its price relative to the market?

18.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CRY ($23.74) is trading below our estimate of fair value ($29.09)

Significantly Below Fair Value: CRY is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CRY is poor value based on its PE Ratio (264.4x) compared to the Medical Equipment industry average (41.8x).

PE vs Market: CRY is poor value based on its PE Ratio (264.4x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: CRY is poor value based on its PEG Ratio (4.7x)


Price to Book Ratio

PB vs Industry: CRY is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is CryoLife forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

55.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRY's forecast earnings growth (55.7% per year) is above the savings rate (2.7%).

Earnings vs Market: CRY's earnings (55.7% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CRY's revenue (8% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: CRY's revenue (8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CRY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CryoLife performed over the past 5 years?

-35.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CRY's earnings have declined by -35.2% per year over the past 5 years.

Accelerating Growth: CRY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CRY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: CRY's Return on Equity (1.2%) is considered low.


Return on Assets

ROA vs Industry: CRY's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: CRY's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is CryoLife's financial position?


Financial Position Analysis

Short Term Liabilities: CRY's short term assets ($188.6M) exceeds its short term liabilities ($37.5M)

Long Term Liabilities: CRY's short term assets (188.6M) do not cover its long term liabilities (277.5M)


Debt to Equity History and Analysis

Debt Level: CRY's debt to equity ratio (76.6%) is considered high

Reducing Debt: Insufficient data to determine if CRY's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: CRY's debt is not well covered by operating cash flow (9.6%).

Interest Coverage: CRY's interest payments on its debt are not well covered by EBIT (1.1x coverage).


Balance Sheet

Inventory Level: CRY has a low level of unsold assets or inventory.

Debt Coverage by Assets: CRY's debt is not covered by short term assets (assets are 0.9x debt).


Next Steps

Dividend

What is CryoLife's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CRY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CRY is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of CryoLife's salary, the management and board of directors tenure and is there insider trading?

5.1yrs

Average management tenure


CEO

Pat MacKin (52yo)

5.1yrs

Tenure

US$3,231,170

Compensation

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of CryoLife Inc. since September 02, 2014 and has been its Chairman since April 9, 2015 and Director since Oc ...


CEO Compensation Analysis

Compensation vs. Market: Pat's total compensation ($USD3.23M) is about average for companies of similar size in the US market ($USD2.67M).

Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.


Management Age and Tenure

5.1yrs

Average Tenure

52yo

Average Age

Experienced Management: CRY's management team is seasoned and experienced (5.1 years average tenure).


Board Age and Tenure

7.4yrs

Average Tenure

62yo

Average Age

Experienced Board: CRY's board of directors are considered experienced (7.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$57,10003 Jun 19
Scott Capps
EntityIndividual
Role
Other Key Executive
Vice President of Clinical Research
Shares2,000
Max PriceUS$28.55
SellUS$44,49929 May 19
Ronald McCall
EntityIndividual
Role
Lead Director
Presiding Director
Shares1,563
Max PriceUS$28.47
SellUS$106,34624 May 19
Ronald McCall
EntityIndividual
Role
Lead Director
Presiding Director
Shares3,700
Max PriceUS$29.02
SellUS$1,565,69007 May 19
James MacKin
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares50,000
Max PriceUS$31.31
SellUS$269,49407 May 19
David Lee
EntityIndividual
Role
Chief Financial Officer
Executive VP
Shares8,589
Max PriceUS$31.38
SellUS$181,39026 Feb 19
Ronald McCall
EntityIndividual
Role
Lead Director
Presiding Director
Shares6,200
Max PriceUS$29.26

Ownership Breakdown


Management Team

  • David Lee (54yo)

    Executive VP

    • Tenure: 19.5yrs
    • Compensation: US$1.26m
  • Amy Horton (49yo)

    VP & Chief Accounting Officer

    • Tenure: 13.2yrs
  • Pat MacKin (52yo)

    Chairman

    • Tenure: 5.1yrs
    • Compensation: US$3.23m
  • Scott Capps (52yo)

    Vice President of Clinical Research

    • Tenure: 11.9yrs
    • Compensation: US$646.00k
  • Thomas Bogenschütz (52yo)

    Senior Vice President of Europe

    • Tenure: 0yrs
  • Jean Holloway (62yo)

    Senior VP

    • Tenure: 4.5yrs
    • Compensation: US$1.03m
  • John Davis (54yo)

    Senior Vice President of Global Sales & Marketing

    • Tenure: 4.1yrs
    • Compensation: US$923.37k
  • Karen Dabbs

    Assistant Corporate Secretary

    • Tenure: 0yrs
  • Mike Simpson (51yo)

    Senior Vice President of Regulatory Affairs & Quality Assurance

    • Tenure: 0.8yrs
  • Joshua Wells

    Senior Director of Business Development

    • Tenure: 0yrs

Board Members

  • Ronald McCall (82yo)

    Presiding Director

    • Tenure: 13.8yrs
    • Compensation: US$192.91k
  • Jim Bullock (62yo)

    Director

    • Tenure: 3yrs
    • Compensation: US$176.87k
  • Thomas Ackerman (64yo)

    Director

    • Tenure: 15.8yrs
    • Compensation: US$183.33k
  • Dan Bevevino (59yo)

    Director

    • Tenure: 15.8yrs
    • Compensation: US$189.79k
  • Harvey Morgan (77yo)

    Director

    • Tenure: 11.4yrs
    • Compensation: US$190.31k
  • Jeff Burbank (56yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$172.39k
  • Jon Salveson (54yo)

    Director

    • Tenure: 7.4yrs
    • Compensation: US$181.35k
  • Pat MacKin (52yo)

    Chairman

    • Tenure: 5.1yrs
    • Compensation: US$3.23m
  • Marna Borgstrom (65yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$139.57k

Company Information

CryoLife, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CryoLife, Inc.
  • Ticker: CRY
  • Exchange: NYSE
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$890.146m
  • Shares outstanding: 37.50m
  • Website: https://www.cryolife.com

Number of Employees


Location

  • CryoLife, Inc.
  • 1655 Roberts Boulevard NW
  • Kennesaw
  • Georgia
  • 30144
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRYNYSE (New York Stock Exchange)YesCommon StockUSUSDFeb 1993
CYLDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1993

Biography

CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company opera ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 23:33
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.